January 25, 2015 6:38 AM ET


Company Overview of Dr. Reddy's Laboratories Ltd.

Company Overview

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment is also engaged in the operation of biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures ...

8-2-337, Road No. 3

Banjara Hills

Hyderabad,  500034


Founded in 1984

18,421 Employees


91 40 4900 2900


91 40 4900 2999

Key Executives for Dr. Reddy's Laboratories Ltd.

Age: 54
Total Annual Compensation: $6.3M
Chairman of The Board
Age: 47
Total Annual Compensation: $7.7M
Compensation as of Fiscal Year 2014.

Dr. Reddy's Laboratories Ltd. Key Developments

Dr. Reddy's Laboratories Ltd. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 01:30 PM

Dr. Reddy's Laboratories Ltd. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 01:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Umang Vohra, Head of North America Generics Business, Executive Vice President and Member of Management Council.

Dr. Reddy’s Laboratories Launches Valganciclovir Tablets USP 450 mg

Dr. Reddy’s Laboratories announced that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE® (Valganciclovir) tablets in the US market on December 15, 2014, approved by the United States Food & Drug Administration (USFDA). Dr. Reddy’s Valganciclovir tablets, USP in 450 mg is available in bottle counts of 60.

Dr. Reddy's Laboratories Ltd. Launches Docetaxel Injection USP

Dr. Reddy's Laboratories announced that is has launched Docetaxel Injection USP 20 mg/mL and 80 mg/4 mL a therapeutic equivalent generic version of TAXOTERE(R) (docetaxel Injection) in the US market on November 21, 2014. Dr. Reddy's ANDA is approved by the United States Food & Drug Administration (USFDA). Dr. Reddy's Docetaxel Injection USP, 20 mg/mL and 80 mg/4 mL are available as a single dose, one vial formulation that does NOT require a prior dilution with a diluent and is ready to add to the Intravenous Infusion solution.

Recent Private Companies Transactions

November 14, 2014
Cherokee Pharma, LLC

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Dr. Reddys Laboratories Ltd., please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.